Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted reduction of concurrent chemotherapy in locally advanced nasopharyngeal carcinoma
ChiCTR2200056868Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Progression-free survival and Distant metastasis-free survival. Started Nov 2020; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200056868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056868.